Retrospective Study

Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients

Xue Yang, Zhi-Jie Xu, Xi Chen, Shuang-Shuang Zeng, Long Qian, Jie Wei, Mei Peng, Xiang Wang, Wan-Li Liu, Hong-Ying Ma, Zhi-Cheng Gong, Yuan-Liang Yan

ORCID number: Xue Yang (0000-0002-7856-5824); Zhi-Jie Xu (0000-0003-2047-883X); Xi Chen (0000-0001-6702-2771); Shuang-Shuang Zeng (0000-0003-3152-0589); Long Qian (0000-0002-1819-5411); Jie Wei (0000-0002-5554-0405); Mei Peng (0000-0001-6381-4958); Xiang Wang (0000-0001-6222-8033); Wan-Li Liu (0000-0002-7315-7856); Hong-Ying Ma (0000-0002-0589-3456); Zhi-Cheng Gong (0000-0002-2404-0942); Yuan-Liang Yan (0000-0001-6610-3617).

Author contributions: Yang X and Xu ZJ designed the research scheme and contributed equally to this article; Yan YL and Gong ZC contributed equally to correspondence about this manuscript; Chen X, Zeng SS, Qian L, and Wei J collected data from the samples; Peng M, Wang X, Liu WL, Xu ZJ, and Ma HY analyzed the data.

Supported by: the National Natural Science Foundation of China, No. 81803035, No. 81703036, and No. 81572946; the China Postdoctoral Science Foundation, No. 2017M610510; and the Youth Fund of Xiangya Hospital, No. 2017Q17.

Institutional review board statement: This study was reviewed and approved by the Ethical Committee of Xiangya Hospital of Central South University (Approval No. 2018111100).

Informed consent statement: According to the “Human Biomedical Research Ethical

Abstract

BACKGROUND
The methylated septin 9 (mSEPT9) assay was the first blood-based test approved by the United States Food and Drug Administration as a colorectal screening test. However, the diagnostic and prognostic role of preoperative mSEPT9 for colorectal cancer (CRC) in Chinese patients is still unknown.

AIM
To improve the understanding of diagnostic and prognostic factors, serum mSEPT9 was detected in Chinese CRC patients.

METHODS
A retrospective analysis of 354 cases, of which 300 had CRC and 54 were normal, was performed in China. Patients’ characteristics, treatments, and laboratory data, including age, the date of surgery, Union for International Cancer Control (UICC) stages, distant metastasis (M), and so on, were collected. Methylation levels of SEPT9 were quantified by quantitative, methylation-specific polymerase chain reaction before surgery. In addition, the effects of mSEPT9 on the occurrence and prognosis of 330 CRC cases from The Cancer Genome Atlas (TCGA) database were evaluated using bioinformatics analyses. Potential prognostic factors for overall survival (OS) and progression-free survival (PFS) were evaluated by Kaplan-Meier univariate analysis.

RESULTS
In Chinese CRC patients, positive mSEPT9 was strongly associated with advanced UICC stages, deeper invasion by the primary tumor, and more distant metastasis. Methylation levels of SEPT9 were stage-dependent and showed a stepwise increase in UICC stages (I–IV), primary tumor categories (T1–T4), regional node categories (N0–N2), and distant metastasis categories (M0–M1). The patients with positive mSEPT9 showed a tendency toward lower PFS. After analyzing TCGA clinical data, the high mSEPT9 group was found to be obviously correlated only with more distant metastasis. The patients with high mSEPT9 levels showed a tendency toward lower OS. Besides, nine meaningful mSEPT9 sites were found to provide guidance for the follow-up studies.

**CONCLUSION**

MSEPT9 analysis may add valuable information to current tumor staging. Serum mSEPT9 in Chinese CRC patients appears to offer promising novel prognostic markers and might be considered for monitoring CRC recurrence.

**Key words:** Methylated septin 9; Methylated; Colorectal cancer; Diagnosis; Prognosis

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** This study retrospectively explored the value of serum septin 9 methylation (mSEPT9) in the diagnosis and prognosis of colorectal cancer in a Chinese population. Preoperative mSEPT9 levels in 354 enrolled patients were retrospectively analyzed. In addition, the effects of mSEPT9 on the occurrence and prognosis of 330 colorectal cancer cases from The Cancer Genome Atlas database were evaluated using bioinformatics analyses. Besides, nine meaningful mSEPT9 sites were found to provide guidance for the follow-up studies.

**Citation:** Yang X, Xu ZJ, Chen X, Zeng SS, Qian L, Wei J, Peng M, Wang X, Liu WL, Ma HY, Gong ZC, Yan YL. Clinical value of preoperative methylated septin 9 in Chinese colorectal cancer patients. *World J Gastroenterol* 2019; 25(17): 2099-2109

**URL:** https://www.wjgnet.com/1007-9327/full/v25/i17/2099.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v25.i17.2099

**INTRODUCTION**

Colorectal cancer (CRC) remains the third most common cancer expected to occur in men and women[1], accounting for approximately 10% of the global cancer burden. To date, more than 90% of patients with early CRC have survived five years after diagnosis[2-3]. However, in the case of regional spread to lymph nodes or adjacent organs, the five-year relative survival rate decreases to 69%, and when there is distant metastasis, it drops sharply to approximately 10%[4-5]. Despite significant recent achievements in the diagnosis and treatment of these patients, resulting in partial reductions in overall incidence and mortality, there is no effective diagnostic assay so far for tumor progression or recurrence monitoring, especially in vitro. Detection of CRC recurrences or metastases in the early stage by constant monitoring may improve long-term outcomes through timely treatment. The American Joint Committee on Cancer (AJCC) Cancer Staging, seventh edition has accepted clinically useful carcinoembryonic antigen (CEA) serum tumor marker as a site-specific prognostic factor in CRC[6]. However, the low detection sensitivity of CEA hinders its use for many surgical patients, because patients with negative CEA results before surgery usually cannot be monitored after surgery[7]. In addition, periodic computed tomography (CT) scanning is another noninvasive method for surgical therapeutic effect assessment[8]. However, CT scans have limited sensitivity and high false positive rates, and cannot be used routinely as a monitoring examination due to the danger of long-term radiation[9]. Therefore, development of novel, sensitive biomarkers for monitoring recurrences or metastases of CRC is urgently needed.

Hypermethylation of the promoter of septin 9 (SEPT9) has previously been shown to be a sensitive and specific biomarker in various cancers including CRC[10-13] and its precursor lesions[14-16]. As a result, the methylated SEPT9 (mSEPT9) assay became the first blood-based test approved by the United States Food and Drug Administration.
as a CRC screening test[17]. A study of Korean CRC patients found that serum mSEPT9 had a tendency to show metastasis and a low disease-free survival rate[18]. In a recent study of German CRC patients, mSEPT9 was significantly associated with Union for International Cancer Control (UICC) stages both before and after therapy[19]. In addition, quantitative mSEPT9 levels have been successfully applied for the diagnosis of CRC[18-22], and for the screening, diagnosis, monitoring, prognosis, and molecular staging of head and neck squamous cell carcinomas (HNSCC)[19]. However, the diagnostic and prognostic role of preoperative mSEPT9 for CRC in Chinese patients is still unknown.

This study assessed the correlation between clinicopathological characteristics and preoperative serum mSEPT9 in Chinese CRC patients and, further, to confirm the correlation between mSEPT9 levels and CRC prognosis by bioinformatics analyses. In addition, we analyzed methylated sites that were co-upregulated or codownregulated in colon and rectum tumors, to provide the theoretical guidance for further research.

**MATERIALS AND METHODS**

**Patients and samples**

This present study was conducted from December 2017 to November 2018 among patients at the Department of Hepatobiliary and Enteric Surgery in Xiangya Hospital. A total of 354 subjects with mSEPT9 serum detection before surgery were recruited from a medicine-pharmacy-nursing integrative parenteral medication rational use and safety early warning platform, the Parenteral Prescription Early Warning and Assessment System, including 300 CRC patients and 54 normal subjects. This study was approved by the Ethical Committee of Xiangya Hospital of Central South University (Approval No. 2018111100).

Three hundred patients presented with histologically confirmed primary CRC. Recurrences or metastases were determined from diagnostic tests (CT scan, magnetic resonance imaging, or colonoscopy) and confirmed through tissue pathology when available[7]. Clinical parameters, including mSEPT9 detection results, gender, age, UICC stage, histologic grade, primary tumor (T) categories, regional node (N) categories, distant metastasis categories (M), lymphatic invasion (L), lymph nodal status, vascular invasion (V), and tumor site, were collected. The UICC stage, tumor node metastasis (TNM) categories and histologic differentiation were graded on the basis of the eighth edition of the AJCC[23]. Progression-free survival (PFS) time was calculated from the CRC patients’ date of surgery to presentation of clinical or pathological evidence of cancer recurrence.

In addition, 330 colorectal adenocarcinomas from The Cancer Genome Atlas (TCGA) Research Network (http://cancergenome.nih.gov/) were selected and analyzed retrospectively. Patients whose mSEPT9 levels were less than or equal to median were assigned to the low mSEPT9 group, whereas others were assigned to the high mSEPT9 group. The overall survival (OS) time was calculated from the CRC patients’ date of surgery to the date of dead or to the last contact date.

**Methylated SEPT9 detection**

A 10 mL peripheral blood sample was collected with a 10 mL K2EDTA anticoagulant tube for the SEPT9 assay [BioChain (Beijing) Science and Technology, Inc., Beijing, China]. Peripheral blood sample storage and transportation, DNA extraction, and bisulfite conversion were performed manually following the manufacturer’s instructions of the Epi proColon 2.0 kit (Epigenomics AG, Berlin, Germany). The mSEPT9 was assayed with the Epi proColon 2.0 kit on an AB7500 Fast Dx Real Time polymerase chain reaction device (Life Technologies) in the Clinical Laboratory of Xiangya Hospital, Central South University. Briefly, a polymerase chain reaction (PCR) test was performed in triplicate with 15 μL template DNA per well and run for 45 cycles[24]. The instrument software was used to record the PCR results for β-actin (ACTB) and methylated SEPT9 from each of the triplicate reactions. The validity of each sample batch was determined according to methylated SEPT9 and ACTB threshold count (Ct) values for the positive and negative controls. ACTB served as an internal reference to assess the integrity of each sample. According to the instructions, Ct value was less than 41.1 was assigned to the positive mSEPT9 group, whereas those whose Ct value was over 41.1 were assigned to the negative mSEPT9 group.

**Statistical analyses**

All statistical analyses were performed using SPSS 18 software (SPSS Inc, Chicago, United States). The measurable data was expressed as the mean and standard deviation (SD). Differences of clinicopathological characteristics and Ct values
between groups were compared via t-tests and χ² test. The univariate analysis was performed to assess the effect of mSEPT9 to predict PFS and OS by the Kaplan-Meier method. Binary logistic regression was used to analyze the association between each genetic biomarker (e.g., mismatched repair proteins) and mSEPT9. All the statistical tests were bilateral, and $P < 0.05$ was considered statistically significant.

RESULTS

The mSEPT9 in CRC patients and normal subjects

Among Chinese CRC patients, the methylated Ct values of 300 primary CRC patients and 54 normal subjects were analyzed. Based on contradictory trends for Ct value and expression, the preoperative serum mSEPT9 levels were significantly higher in CRC patients than in the normal subjects ($P = 0.008$) (Figure 1A). The positive rate of mSEPT9 was 52.3% for CRC patients and 25.9% for normal subjects ($P = 0.102$) (Figure 1B).

Among 351 patients from the TCGA database, the mSEPT9 levels of 330 CRC patients and 21 normal subjects were analyzed. The serum mSEPT9 levels of the CRC patients were higher than those of the normal subjects, but were not statistically significant ($P = 0.530$) (Supplemental Figure 1).

Clinicopathological characteristics and mSEPT9 in CRC

The Chinese CRC patients, clinicopathological features of 300 CRC patients are described in Table 1. As shown in Figure 1C, patients older than 50 years were statistically more numerous than those aged 50 or younger in both positive and negative groups ($P = 0.016$). Through analyzing UICC stages, we found that the positive rate of stage III was observably higher than stage I (46.6% vs 31.0%, $P = 0.012$) (Figure 2A); mSEPT9 levels showed a significant increase from UICC stages II to III ($P = 0.033$) and stages III to IV ($P < 0.0001$), but no obvious difference was detected between stages I to II ($P = 0.898$, Figure 3A).

In addition, the association of mSEPT9 levels and rate of positive mSEPT9 among primary tumor categories (T1–T4), regional node categories (N0–N2) and distant metastasis categories (M0–M1) were also analyzed. The detection rate of positive T3 was observably higher than that of T1 (51.1% vs 40.0%, $P = 0.019$) (Figure 2B). Positive rate and levels of mSEPT9 revealed a significant increase from T3 to T4 ($P = 0.030$, $P = 0.046$, respectively) (Figure 2B, Figure 3B). In terms of regional node categories, N0 to N2 showed a gradual increase in mSEPT9 levels ($P = 0.012$) (Figure 3C), but did not show any association with the rate of positive mSEPT9 (Figure 2C). As shown in Figures 2D and 3D, mSEPT9 showed the best ability to discriminate between local and metastatic CRC ($P = 0.015$, $P < 0.0001$, respectively). However, higher mSEPT9 levels were not found in CRC patients with lymphatic or vascular invasion than in those without invasion (all $P > 0.05$). We also failed to find association among MLH1, MSH2 (25D12), MSH6, PM2S, and KI67 and mSEPT9 (all $P > 0.05$) (Supplemental Table 1).

In further analyzed TCGA clinical data, 124 mSEPT9 sites were found that showed differential expression among normal subjects and those with colon and rectum adenocarcinoma, respectively (all $P < 0.05$) (Supplemental Figure 2). After analyzing the detailed information of these 124 mSEPT9 sites, 68 co-upregulated and 36 co-downregulated mSEPT9 sites in CRC adenocarcinoma were further observed. We finally confirmed that there were eight co-upregulated mSEPT9 sites (Figure 5) and

Prognostic significance of mSEPT9 in CRC patients

Kaplan-Meier univariate analysis showed that positive mSEPT9 was obviously associated with shorter PFS among the Chinese CRC patients ($P = 0.019$, Figure 4A). The positive mSEPT9 CRC cases were estimated to have an mean PFS duration of 3.7 mo [95% confidence interval (CI): 2.14-5.19] compared with the 6.0 mo (95%CI: 0-13.87) in the negative mSEPT9 CRC cases.

In addition, serum mSEPT9 showed prognostic significance for the CRC patients from the TCGA database ($P = 0.008$, Figure 4B). CRC patients with low mSEPT9 levels were found to be correlated with longer OS. The low mSEPT9 CRC cases had an estimated mean OS duration of 8.1 months (95%CI: 6.53-9.27) compared with the 5.1 mo (95%CI: 3.87-6.33) in the high mSEPT9 group, but no significant difference was found in UICC stages, primary tumor categories, or regional node categories (all $P > 0.05$).

Significant methylation sites for SEPT9

In further analyzed TCGA clinical data, 124 mSEPT9 sites were found that showed differential expression among normal subjects and those with colon and rectum adenocarcinoma, respectively (all $P < 0.05$) (Supplemental Figure 2). After analyzing the detailed information of these 124 mSEPT9 sites, 68 co-upregulated and 36 co-downregulated mSEPT9 sites in CRC adenocarcinoma were further observed. We finally confirmed that there were eight co-upregulated mSEPT9 sites (Figure 5) and
Figure 1  Graphical representations of difference in methylated septin 9 Cl values or proportion of patients between different groups. A: Methylated septin 9 (mSEPT9) Ct values in tumor group and normal group; B: Proportion of patients with positive and negative mSEPT9 in tumor group and normal group; C: Proportion of patients older than 50 and aged 50 or younger in positive group and negative group. The statistical significance for difference of means is shown in P values, t-test, or χ² test. mSEPT9: Methylated septin 9.

one co-downregulated mSEPT9 site (cg02975107) through setting a cut-off of a two-fold expression change of mSEPT9.

DISCUSSION

Most patients with early CRC undergo curatively intended surgery to clear up primary lesions and local lymph node metastasis up. However, 30%-50% of patients would still confront tumor recurrence and might die from metastasis[25]. Timely monitoring of recurrence and metastasis is of great significance to the prognosis and survival of patients. In our study, mSEPT9 was proved to be an effective biomarker for diagnosis, recurrence, and prognosis of CRC in Chinese patients, and nine significant mSEPT9 sites were confirmed for further in-depth consideration.

Our study confirmed the value of serum mSEPT9 for CRC diagnosis. Compared with normal tissues in Chinese and TCGA data, serum SEPT9 was found to be hypermethylated in tumor tissues, which was consistent with previous studies[18,19,26]. Studies showed that age affected the detection rate of the SEPT9 assay[27,28], and we found that a positive rate of mSEPT9 was strongly associated with CRC patients aged over 50 years both in Chinese and TCGA data. This accords with the definition of an average risk population in National Comprehensive Cancer Network Guidelines for CRC[29]. Remarkably, we reported that SEPT9 performs outstandingly as an auxiliary molecular staging parameter in the Chinese population, especially because mSEPT9 levels could distinguish between pathological UICC and TNM stages in an incremental fashion. In addition, our data demonstrated that CRC patients in earlier tumor stages showed lower mSEPT9 levels compared to those with more advanced lesions, which is consistent with studies in German CRC patients[19,30-32]. Most importantly, its ability to identify patients with distant metastases emphasizes the potential of mSEPT9 as a bio-marker, which adds valuable information to the classification of tumors[33-35]. However, high mSEPT9 group did not show any association with UICC, T, or N stages in patients from the TCGA database, who were from American Indian, Asian, Black, or African American populations. This might be explained by the different study populations. Previous studies found that the incidence of CRC and the sensitivity to the mSEPT9 test assay in different ethnic groups were different[14,36].

In addition, serum mSEPT9 were proved to be an independent predictors of CRC recurrence and unfavorable cancer-specific survival in Chinese and TCGA data, which is consistent with previous studies in Singapore and Germany[19,37,38]. The study was performed with a large number of prognostic features and patients; however, much longer prognosis and follow-up time are necessary before final conclusions can be made, and the increasing number of patients with earlier-stage CRC demands a widening of the clinical importance of predictive value for prognosis.

After further analysis of the TCGA clinical data, we obtained nine SEPT9 methylation sites that show two-fold higher or lower mSEPT9 levels in CRC than normal tissues. However, no studies were found at present that investigate the prognosis of these methylation sites and CRC was found. Surprisingly, cg12783819, which only shows 1.5-fold higher mSEPT9 levels in CRC than in normal tissues, has been proven to be able to assess the diagnosis, prognosis, and molecular staging of
Table 1  Clinicopathological characteristics based on methylated septin 9 status in 300 colorectal cancer patients

| Parameter                     | Positive group (%) | Negative group (%) | P      |
|-------------------------------|--------------------|--------------------|--------|
| **Gender**                    |                    |                    |        |
| Male                          | 84 (28.0)          | 81 (27.0)          | 0.585  |
| Female                        | 73 (24.3)          | 62 (20.7)          |        |
| **Age**                       |                    |                    |        |
| ≤ 50 yr                       | 45 (15.0)          | 60 (20.0)          | 0.016  |
| > 50 yr                       | 112 (37.3)         | 85 (27.7)          |        |
| **UICC stage**                |                    |                    |        |
| I                             | 9 (3.0)            | 20 (6.7)           | 0.020  |
| II                            | 46 (15.3)          | 32 (10.7)          |        |
| III                           | 62 (20.6)          | 71 (23.7)          |        |
| IV                            | 13 (4.3)           | 6 (2.0)            |        |
| Unknown                       | 27 (9.0)           | 14 (4.7)           |        |
| **Histologic grade**          |                    |                    |        |
| Low level                     | 115 (38.3)         | 103 (34.3)         | 0.972  |
| High level                    | 18 (6.0)           | 17 (5.7)           |        |
| Not recorded                  | 24 (8.0)           | 25 (7.7)           |        |
| **Primary tumor (T) category**|                    |                    |        |
| T1                            | 2 (0.7)            | 3 (1.0)            | 0.002  |
| T2                            | 15 (5.0)           | 23 (7.7)           |        |
| T3                            | 70 (23.3)          | 67 (22.3)          |        |
| T4                            | 40 (13.3)          | 34 (11.3)          |        |
| Not recorded                  | 30 (10.0)          | 16 (5.3)           |        |
| **Regional node (N) category**|                    |                    |        |
| N0                            | 57 (19.0)          | 23 (7.7)           | 0.852  |
| N1                            | 32 (10.7)          | 67 (22.3)          |        |
| N2                            | 37 (12.3)          | 34 (11.3)          |        |
| Not recorded                  | 31 (10.3)          | 16 (5.3)           |        |
| **Distant metastasis (M)**    |                    |                    |        |
| Absent                        | 141 (47.0)         | 137 (45.7)         | 0.015  |
| Present                       | 16 (5.3)           | 6 (2.0)            |        |
| **Lymphatic invasion (L)**    |                    |                    |        |
| Absent                        | 58 (19.3)          | 60 (20.0)          | 0.217  |
| Present                       | 51 (17.0)          | 52 (17.3)          |        |
| Not recorded                  | 48 (16.0)          | 31 (10.3)          |        |
| **Lymph nodal status**        |                    |                    |        |
| No node involved              | 51 (17.0)          | 52 (17.3)          | 0.048  |
| 1-3 lymph node involved       | 27 (9.0)           | 40 (13.3)          |        |
| > 4 lymph node involved       | 31 (10.3)          | 20 (6.7)           |        |
| Not recorded                  | 48 (16.0)          | 31 (10.3)          |        |
| **Vascular invasion (V)**     |                    |                    |        |
| Absent                        | 36 (12.0)          | 31 (10.3)          | 0.278  |
| Present                       | 70 (23.3)          | 76 (25.3)          |        |
| Not recorded                  | 51 (17.0)          | 36 (12.0)          |        |
| **Tumor site**                |                    |                    |        |
| Left colon                    | 44 (14.7)          | 31 (10.3)          | 0.022  |
| Right colon                   | 27 (9.0)           | 11 (3.7)           |        |
| Rectum                        | 74 (24.7)          | 86 (28.6)          |        |
| Unable to distinguish         | 12 (4.0)           | 15 (5.0)           |        |

*Right colon includes cecum through transverse colon, whereas left colon includes splenic flexure, descending colon, and sigmoid colon. Clinicopathological characteristics between positive group and negative group were analyzed using χ² test. UICC: Union for International Cancer Control.

German HNSCC and CRC patients[19,20]. The result prompts us to explore the potential association between these nine methylation sites and in Chinese CRC patients in the future.

In conclusions, serum SEPT9 methylation testing is a powerful additional diagnostic tool and promising, novel prognostic markers. Patients with initially high mSEPT9 levels may benefit from intensive therapy and close monitoring of disease development, thereby improving outcomes for CRC patients. These patients may benefit from early systemic treatment.
Figure 2  Graphical representations of the proportion of patients with positive and negative methylated septin 9 with different tumor status. A: Union for International Cancer Control stages; B: Primary tumor categories; C: Regional node categories; D: Distant metastasis categories. The statistical significance for difference of means is shown in \( P \) values and \( \chi^2 \) test.

Figure 3  Graphical representations of methylated septin 9 Ct values in different tumor status. A: Union for International Cancer Control stages; B: Primary
tumor categories; C: Regional node categories; D: Distant metastasis categories. The statistical significance for difference of means is shown in \( P \) values and \( t \)-test.

\( \text{mSEPT9: Methylated septin 9.} \)

**ARTICLE HIGHLIGHTS**

**Research background**
The methylated septin 9 (mSEPT9) assay was the first blood-based test approved by the United States Food and Drug Administration as a colorectal screening test. Previous researchers found that mSEPT9 was a powerful screening, diagnostic, monitoring, and prognostic tool for German colorectal cancer (CRC) patients. However, the diagnostic and prognostic value of mSEPT9 in Chinese CRC patients is still unknown, and may be affected by differences in ethnicity and socioeconomic status.

**Research motivation**
To explore the diagnostic and prognostic value of serum mSEPT9 for Chinese CRC patients.

**Research objectives**
This study aimed to explore the diagnostic value of preoperative serum mSEPT9 in the Chinese population, and then assess the value of quantitative mSEPT9 levels for CRC staging. In addition, Chinese population and TCGA database information were combined to determine the prognostic significance of mSEPT9 by bioinformatics analyses.
Research methods
Three hundred fifty-four subjects (300 CRC, 54 normal) from China and 351 subjects (330 CRC, 21 normal) from the TCGA database including American Indian, Asian, Black, and African American populations were retrospectively analyzed. Preoperative mSEPT9 levels were quantified by quantitative methylation-specific polymerase chain reaction. Kaplan-Meier univariate assay was performed to analyze potential prognostic factors including overall survival (OS) and progression-free survival (PFS).

Research results
In Chinese CRC patients, positive mSEPT9 and quantitative mSEPT9 levels were strongly associated with clinico-pathological parameters. The patients with positive mSEPT9 showed a tendency toward lower PFS. Higher mSEPT9 levels were correlated with more distant metastasis among the TCGA database patients, and patients with high mSEPT9 levels showed a tendency toward lower OS.

Research conclusions
Testing for mSEPT9 is a powerful diagnostic and promising prognostic tool for Chinese CRC patients; it may add valuable information to current tumor staging and holds the potential to monitor CRC recurrence.

Research perspectives
This study assessed the correlation between clinicopathological characteristics and preoperative serum mSEPT9 in Chinese CRC patients and, further, to confirm the correlation between mSEPT9 levels and CRC prognosis by bioinformatics analyses. In addition, we analyzed methylated sites that were co-upregulated or co-downregulated in colon and rectum tumors, to provide the theoretical guidance for further research.

REFERENCES

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2018. CA Cancer J Clin 2018; 68: 7-30 [PMID: 29313949 DOI: 10.3322/caac.21442]
2. Bresalier RS, Kopetz S, Brenner DE. Blood-based tests for colorectal cancer screening: Do they threaten the survival of the FIT test? Dig Dis Sci 2015; 60: 664-671 [PMID: 25680874 DOI: 10.1007/s10620-015-3575-2]
3. Siegel R, Desantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerco C, Fedewa S, Lin C, Leach C, Cramyady RS, Cho H, Scoppa S, Flachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62: 220-241 [PMID: 22700443 DOI: 10.3322/caac.21149]
4. Li Y, Song L, Gong Y, He B. Detection of colorectal cancer by DNA methylation biomarker SEPT9: Past, present and future. Biomark Med 2014; 8: 755-769 [PMID: 25512042 DOI: 10.2217/bmm.14.8]
5. Cucurullo V, Masini L. AJCC Cancer Staging Handbook: from the AJCC Cancer Staging Manual (7th edition). Eur J Nucl Med Mol Imaging 2011; 38: 408-408 [DOI: 10.1007/978-0-387-88443-1_14]
6. Young GP, Pedersen SK, Mansfield S, Murray DH, Baker RT, Rabbitt P, Byrne S, Bambacas L, Hoggard P, Symonds EL. A cross-sectional study comparing a blood test for methylated BCAT1 and IKZF1 tumor-derived DNA with CEA for detection of recurrent colorectal cancer. Cancer Med 2016; 5: 2763-2772 [PMID: 27726312 DOI: 10.1002/cam4.868]
7. Nicholson BD, Shinkinis B, Pathiraja I, Roberts NW, James TJ, Mallett S, Perera R, Primrose JN, Mant D. Blood CEA levels for detecting recurrent colorectal cancer. Cochrane Database Syst Rev 2015; CD011134 [PMID: 26661580 DOI: 10.1002/14651858.CD011134.pub2]
8. Ng SB, Chua C, Gan A, Poon PS, Teo M, Fu C, Leow WQ, Lim KH, Chung A, Koo SL, Choo SP, Ho D, Rrozen S, Tan P, Wong M, Burkeholder WF, Tan IB. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Sci Rep 2017; 7: 40737 [PMID: 28102343 DOI: 10.1038/srep40737]
9. Metser U, You J, McSweeney S, Freeman M, Hendler A. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. J Br J Radiol 2010; 83: 766-771 [PMID: 20173157 DOI: 10.2214/BRJ.09.3205]
10. Song L, Jia J, Peng X, Xiao W, Li Y. The performance of the SEPT9 gene methylation assay and a comparison with other CRC screening tests: A meta-analysis. Sci Rep 2017; 7: 3032 [PMID: 28596563 DOI: 10.1038/s41598-017-03231-5]
11. Song L, Li Y. Progress on the clinical application of the SEPT9 gene methylation assay in the past 5 years. Biomark Med 2017; 11: 415-418 [PMID: 28617104 DOI: 10.2217/bmm-2017-0091]
12. Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, Fang JC, Samowitz WS, Warren JD, Xiong W, Bunker AM, Vaughn CP, Furtado LV, Roberts WL, Fang JC, Samowitz WS, Heichman KA. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer. BMC Med 2011; 9: 133 [PMID: 22168215 DOI: 10.1186/1741-7015-9-133]
13. Song LL, Li YM. Current noninvasive tests for colorectal cancer screening: An overview of colorectal cancer screening tests. World J Gastrointest Oncol 2016; 8: 793-800 [PMID: 27895817 DOI: 10.4251/wjgo.v8.i8.793]
14. Song L, Li Y. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer. Adv Clin Chem 2015; 72: 171-204 [PMID: 26471083 DOI: 10.1016/bs.acc.2015.07.004]
15. Liu S, Xiao Z, Ai F, Liu F, Chen X, Cao K, Ren W, Zhang X, Shu P, Zhang D. Corrigendum to “miR-142-5p promotes development of colorectal cancer through targeting SDHB and facilitating generation of aerobic glycolysis” [Biomed. Pharmacother. 92 (2017) 1119-1127]. Biomed Pharmacother 2018; 99: 1033-1036 [PMID: 29398246 DOI: 10.1016/j.biopha.2018.01.031]
16. Semaan A, van Ellen A, Meller S, Berghem D, Branchi V, Linghoef P, Goltz D, Kalff JC, Kristianssens G, Matthai H, Pantelis D, Dietrich D. SEPT9 and SHOX2 DNA methylation status and its utility in the...
Yang X et al. Prognostic biomarker of colorectal cancer

diagnosis of colonic adenomas and colorectal adenocarcinomas. *Clin Epigenetics* 2016; 8: 100 [PMID: 27606666 DOI: 10.1186/s13148-016-0267-5]

Church TR, Wandell M, Lothian-Day C, Morgin SJ, Burger M, Payne SR, Castañó-Véllez E, Blumenstein BA, Köch T, Osborn N, Snover D, Day RW, Ransohoff DF; PRESEPT Clinical Study Steering Committee, Investigators and Study Team. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. *Gut* 2014; 63: 317-325 [PMID: 23408352 DOI: 10.1136/gutjnl-2012-304149]

Lee HS, Hwang SM, Kim TS, Kim DW, Park DJ, Kang SB, Kim HH, Park KU. Circulating methylated spectrin 9 nucleic Acid in the plasma of patients with gastrointestinal cancer in the stomach and colon. *Tumour Biol* 2013; 6: 290-296 [PMID: 23730400 DOI: 10.1593/tm.122911]

Bergheim J, Sernaan A, Gevensleben H, Groening S, Knoch M, Dietrich J, Weber J, Kalff J, Beetz F, Krüger K, Dietrich D. Potential of quantitative SEPT9 and SHOX2 methylation in plasticam circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: A prospective observational cohort study. *Br J Cancer* 2018; 118: 1217-1228 [PMID: 29610456 DOI: 10.1016/j.bjoc.2018-03-005-8]

Schröck F, Leise M, de Vos L, Gevensleben H, Dringe F, Fransen A, Wachendorf F, Schröck F, Ellinger J, Teschke M, Wilhelm-Buchtast T, Landsberg J, Holdenhöfer S, Hartmann G, Field JK, Beetz F, Krüger K, Dietrich D. Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study. *Clin Chem* 2017; 63: 1288-1296 [PMID: 28515160 DOI: 10.1373/chinem.2016.270207]

Wu A, He S, Li J, Liu L, Cui W, Wang Q, Peng X, Zhou J, Cao PG, Cao K. Colorectal cancer in cases of multiple primary cancers: Clinical features of 59 cases and point mutation analyses. *Oncol Lett* 2017; 13: 4702-4726 [PMID: 28599473 DOI: 10.3892/ol.2017.6097]

Yao H, Hu H, Liu Y. [Improvement of prognostic and predictive network of colorectal cancer based upon the 8th edition of AJCC colorectal cancer staging system]. *Zhonghua Wei Chang Wai Ke Za Zhi* 2017; 20: 24-27 [PMID: 28105615]

Wu D, Zhou G, Jin P, Zhu J, Li S, Wu Q, Wang G, Sheng J, Wang J, Song L, Han X, Qian J. Detection of Colorectal Cancer Using a Simplified SEPT9 Gene Methylation Assay Is a Reliable Method for Opportunistic Screening. *J Med Diag* 2016; 18: 535-545 [PMID: 27133379 DOI: 10.1016/j.jmed.2016.02.005]

Allemanni C, Rachet B, Weir HK, Richardson LC, Legape C, Faire J, Gatta G, Capocaccia R, Sant M, Biasi P, Lombardo C, Arendt A, Aranda A, Bielska-Lasota M, Bolick S, Cress R, Ellerink M, Fulton JP, Galceran J, Gózdz S, Hukulin T, Primic-Zakelj M, Rachtan J, Diba CS, Sánchez MJ, Schymura MJ, Shen T, Tagliafuoro G, Tomin R, Vercelli M, Wolf H, Wu X, Wu YC, Coleman MP. Colorectal cancer survival in the USA and Europe: A CONCORD high-resolution study. *BMJ Open* 2013; 3: e003055 [PMID: 24022388 DOI: 10.1136/bmjopen-2013-003055]

Fu B, Yan P, Zhang S, Lu Y, Pan L, Tang W, Chen S, Chen Z, Zhang A, Liu Y. Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer. *Dis Markers* 2018; 2018: 6437104 [PMID: 29849824 DOI: 10.1155/2018/6437104]

Song L, Jia J, Yu H, Peng X, Xiao W, Gong Y, Zhou Y, Guo H, Xiao Y. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. *J Cancer Res Clin Oncol* 2017; 143: 1093-1101 [PMID: 28242298 DOI: 10.1007/s00432-017-2363-0]

Ren W, Shen S, Sun Z, Shu P, Shen X, Bu C, Ai P, Zhang X, Tang A, Tian L, Li G, Li X, Ma J. Jak-STAT3 pathway triggers DICER1 for prognostic degradation by ubiquitin ligase complex of CUL4A(DCAF1) to promote colon cancer development. *Cancer Lett* 2016; 375: 209-220 [PMID: 26695998 DOI: 10.1016/j.canlet.2016.02.055]

Provenzale D, Gupta S, Ahnjen DJ, Markowitz AJ, Chung DC, Mayer RJ, Regenbogen SE, Blanco AM, Bray T, Cooper G, Early DS, Ford JM, Giardiello FM, Grady W, Hall MJ, Halverson AL, Hamilton SR, Hampel H, Klappan JB, Larson DW, Lanza A, Li Y, Lior Y, Lynch PM, Mehta JS, Nuss RM, Slavin TP, Sugandala S, Weiss JM, Dwyer MA, Ogbu N. NCCN Guidelines Insights: Colorectal Cancer Screening, Version 1.2018. *J Natl Compr Canc Netw* 2018; 16: 939-949 [PMID: 30099370 DOI: 10.6004/jnccn.2018.0087]

Tóth K, Sipos F, Kalmar’ A, Patai AV, Wichmann B, Stoehr R, Golcher H, Tóth K, Molnár B. Detection of methylated SEPT9 in plasma is a reliable screening method for both left- and right-sided colon cancers. *PloS One* 2012; 7: e46000 [PMID: 23044919 DOI: 10.1371/journal.pone.0046000]

Tóth K, Wasserkröp D, Sipos F, Kalmar’ A, Wichmann B, Leisztet K, Válcs G, Hujász M, Miheller P, Patai AV, Tóth K, Molnár B. Detection of methylated spectrin 9 in tissue and plasma of colorectal patients with neoplasia and the relationship to the amount of circulating cell-free DNA. *PloS One* 2014; 9: e115415 [PMID: 25526039 DOI: 10.1371/journal.pone.0115415]

Chen J, Wang W, Zhang Y, Hu T, Chen Y. The roles of miR-200c in colonic cancer and angiogenesis and associated molecular mechanisms. *Tumour Biol* 2014; 35: 6475-6483 [PMID: 24682933 DOI: 10.1007/s13277-014-1863-x]

Choi AH, Nelson RA, Schoelhammer HF, Cho W, Ko M, Arrington A, Oxner CR, Fakih M, Wong J, Sentovich SM, Garcia-Aguilar J, Kim J. Accuracy of computed tomography in nodal staging of colon and rectal cancer patients. *World J Gastrointest Surg* 2015; 7: 116-122 [PMID: 26225194 DOI: 10.4240/wjgs.v7.i17.116]

Sjövall A, Molnár B, Tóth K, Tóth K, Molnár B, Johansson H, Martling A. Accuracy of preoperative T and N staging in colon cancer—a national population-based study. *Colorectal Dis* 2016; 18: 73-79 [PMID: 26291535 DOI: 10.1111/codi.13991]

Brouwer NPM, Stijns RCH, Lemmens VEEP, Nagtegaal ID, Beets-Tan RGH, Fütterer JJ, Tans PJ, Verhoeven RHA, de Wit HW. Clinical lymph node staging in colorectal cancer; a flip of the coin? *Eur J Surg Oncol* 2018; 44: 1241-1246 [PMID: 29739628 DOI: 10.1016/j.ejsuro.2018.04.008]

Olliering Dj, Nonuma AM, Wilkens LR, Henderson BE, Kolomel LN. Racial/ethnic differences in colorectal cancer risk: The multiethnic cohort study. *Int J Cancer* 2011; 129: 1899-1906 [PMID: 21128280 DOI: 10.1002/ijc.25822]

Tham M, Chew M, Soong R, Lim J, Ang M, Tang C, Zhao Y, Ong SY, Liu Y. Postoperative serum methylations levels of TA1 and SEPT9 are independent predictors of recurrence and survival of patients with colorectal cancer. *Cancer* 2014; 120: 3131-3141 [PMID: 24925595 DOI: 10.1002/cncr.28002]
Song L, Guo S, Wang J, Peng X, Jia J, Gong Y, Yang B, Xiao W, Dong C, Liu H, Li Y. The blood mSEPT9 is capable of assessing the surgical therapeutic effect and the prognosis of colorectal cancer. Biomark Med 2018; 12: 961-973 [PMID: 30043648 DOI: 10.2217/bmm-2018-0012]
